[The prognosis of pulmonary embolism: are there practical implications for patient management?].
There is growing evidence that outpatient treatment is safe and effective for many patients with non-massive pulmonary embolism. Despite this evidence, the vast majority of patients with non-massive pulmonary embolism continue to be treated in an inpatient setting. A major barrier to outpatient treatment has been the lack of explicit criteria to identify patients with pulmonary embolism at low-risk of adverse medical outcome. This article discusses new risk stratification tools for pulmonary embolism such as echocardiography, biomarkers, and clinical prognostic scores, and their potential application for patient management.
Aujesky
D
D
Service de médecine interne, BH 10-622, CHUV, Lausanne. drahomir.aujesky@chuv.ch
Mazzolai
L
L
Perrier
A
A
D000925:Anticoagulants / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D004452:Echocardiography; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011379:Prognosis; D011655:Pulmonary Embolism / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D018570:Risk Assessment; D013557:Switzerland; D014336:Troponin / Q000097:blood
D000925:Anticoagulants; D015415:Biomarkers; D014336:Troponin; D020097:Natriuretic Peptide, Brain; D006493:Heparin